Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity

References

• Boussios S, Pentheroudakis G, Katsanos K, et al. Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. Ann Gastroenterol. 2012;25(2):106–118.
   Google Scholar
• Kehrer DFS, Sparreboom A, Verweij J, et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res. 2001;7(5):1136–1141.
   Google Scholar
• Paranjpe R, Basatneh D, Tao G, et al. Neratinib in HER2-positive breast cancer patients. Ann Pharmacother. 2019;53(6):612–620.
   Google Scholar
• Takimoto CH, Lu ZH, Zhang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 1996;2(3):477–481.
   Google Scholar
• Innocenti F, Iyer L, Ramírez J, et al. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos. 2001;29(5):686–692.
   Google Scholar
• Tao G, Chityala PK, Ghose R. Differential regulation of hepatic UDP ‐ glucuronosyltransferase (UGT) 1A1 by toll ‐ like receptors during irinotecan ‐ induced steatosis. Faseb J. 2020;34(S1):9–11.
   Google Scholar
• Durmus S, Hendrikx JJMA, Schinkel AH. Apical ABC transporters and cancer chemotherapeutic drug disposition. 1st ed. Advances in Cancer Research. Academic Press; 2015. DOI:10.1016/bs.acr.2014.10.001.
   Google Scholar
• Prueksaritanont T, Gorham LM, Hochman JH, et al. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab Dispos. 1996;24(6):634–642.
   Google Scholar
• Obach RS, Zhang Q, Dunbar D, et al. METABOLIC CHARACTERIZATION OF THE MAJOR HUMAN SMALL INTESTINAL CYTOCHROME P450S. Drug Metab Dispos. 2001;29(3):347–352.
   Google Scholar
• Xie F, Ding X, Zhang QY. An update on the role of intestinal cytochrome P450 enzymes in drug disposition. Acta Pharm Sin B. 2016;6(5):374–383.
   Google Scholar
• Dressman JB, Thelen K. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol. 2009;61(5):541–558.
   Google Scholar
• De Buck S, Kucher K, Hara H, et al. CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib. Biopharm Drug Dispos. 2018;39(8):394–402.
   Google Scholar
• Wu B, Kulkarni K, Basu S, et al. First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. J Pharm Sci. 2012;101(7):2271–2280.
   Google Scholar
• Ramachandran A, Jaeschke H. Acetaminophen toxicity: novel insights into mechanisms and future perspectives. Gene Expr. 2018;18(1):19–30.
   Google Scholar
• Klopčič I, Dolenc MS. Chemicals and drugs forming reactive quinone and quinone imine metabolites. Chem Res Toxicol. 2019;32(1):1–34.
   Google Scholar
• Rademacher PM, Woods CM, Huang Q, et al. Differential oxidation of two thiophene-containing regioisomers to reactive metabolites by cytochrome P450 2C9. Chem Res Toxicol. 2012;25(4):895–903.
   Google Scholar
• Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther. 2005;106(3):357–387.
   Google Scholar
• Petriello MC, Hoffman JB, Sunkara M, et al. Dioxin-like pollutants increase hepatic flavin containing monooxygenase (FMO3) expression to promote synthesis of the pro-atherogenic nutrient biomarker trimethylamine N-oxide from dietary precursors. J Nutr Biochem. 2016;33:145–153.
   Google Scholar
• Shibutani S, Dasaradhi L, Terashima I, et al. α-hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res. 1998;58(4):647–653.
   Google Scholar
• Monien BH, Herrmann K, Florian S, et al. Metabolic activation of furfuryl alcohol: formation of 2-methylfuranyl DNA adducts in Salmonella typhimurium strains expressing human sulfotransferase 1A1 and in FVB/N mice. Carcinogenesis. 2011;32(10):1533–1539.
   Google Scholar
• Sachse B, Meinl W, Glatt H, et al. The effect of knockout of sulfotransferases 1a1 and 1d1 and of transgenic human sulfotransferases 1A1/1A2 on the formation of DNA adducts from furfuryl alcohol in mouse models. Carcinogenesis. 2014;35(10): 2339–2345. DOI:10.1093/carcin/bgu152.
   Google Scholar
• Li R, Li W, You Y, et al. Metabolic activation and cytotoxicity of aloe-emodin mediated by sulfotransferases. Chem Res Toxicol. 2019;32(6):1281–1288.
   Google Scholar
• Stocco G, Cheok MH, Crews KR, et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther. 2009;85(2):164–172.
   Google Scholar
• An HR, Wu XQ, Wang ZY, et al. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol. 2012;39(6):535–543.
   Google Scholar
• Wassenaar CA, Dong Q, Wei Q, et al. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst. 2011;103(17):1342–1346.
   Google Scholar
• Matsumoto K, Ikawa K, Abematsu K, et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents. 2009;34(1):91–94.
   Google Scholar
• Yi J, Zhou HH. Polymorphism of UDP-glucuronosyltransferase 1A gene and drug metabolism. Curr Drug Metab. 2007;38(3):235–238.
   Google Scholar
• Guillemette C, Millikan RC, Newman B, et al. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res. 2000;60(4):950–956.
   Google Scholar
• Rouits E, Boisdron-Celle M, Dumont A, et al. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients. Clin Cancer Res. 2004;10(15):5151–5159.
   Google Scholar
• Barbier O, Torra IP, Sirvent A, et al. FXR induces the UGT2B4 enzyme in hepatocytes: A potential mechanism of negative feedback control of FXR activity. Gastroenterology. 2003;124(7):1926–1940.
   Google Scholar
• Barbier O, Duran-Sandoval D, Pineda-Torra I, et al. Peroxisome proliferator-activated receptor α induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J Biol Chem. 2003;278(35):3252–3260.
   Google Scholar
• Khera S, Trehan A, Bhatia P, et al. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2019;83(2):341–348.
   Google Scholar
• Alexander JL, Wilson ID, Teare J, et al. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol. 14(6): 356–365. 2017. .
   Google Scholar
• Selwyn FP, Cheng SL, Klaassen CD, et al. Regulation of hepatic drug-metabolizing enzymes in germ-free mice by conventionalization and probiotics. Drug Metab Dispos. 2016 Feb 1;44(2):262–274.
   Google Scholar
• Wilson ID, Nicholson JK. Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl Res. 2017;179:204–222.
   Google Scholar
• Robertson LW, Chandrasekaran A, Reuning RH, et al. Reduction of digoxin to 20R-dihydrodigoxin by cultures of Eubacterium lentum. Appl Environ Microbiol. 1986;51(6):1300–1303.
   Google Scholar
• Haiser HJ, Seim KL, Balskus EP, et al. Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes. 2014;5:2.
   Google Scholar
• Koppel N, Rekdal VM, Balskus EP. Chemical transformation of xenobiotics by the human gut microbiota. Science. 2017;356(6344):1246–1257.
   Google Scholar
• Baek MC, Kwon AR, Chung YJ, et al. Distribution of bacteria with the arylsulfate sulfotransferase activity. Arch Pharm Res. 1998;21(4): 475–457. DOI:10.1007/BF02974646.
   Google Scholar
• Choi MS, Yu JS, Yoo HH, et al. The role of gut microbiota in the pharmacokinetics of antihypertensive drugs. Pharmacol Res. 2018;130:164–171.
   Google Scholar
• Ogura K, Nishiyama T, Takubo H, et al. Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil derived from the antiviral, sorivudine. Cancer Lett. 1998;122(1–2):107–113.
   Google Scholar
• Nakayama H, Kinouchi T, Kataoka K, et al. Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Pharmacogenetics. 1997:35–43. DOI: 10.1097/00008571-199702000-00005.
   Google Scholar
• Sun R, Zhu L, Li L, et al. Irinotecan-mediated diarrhea is mainly correlated with intestinal exposure to SN-38: critical role of gut Ugt. Toxicol Appl Pharmacol. 2020;398.
   Google Scholar
• Wallace BD, Wang H, Lane KT, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 330(6005): 831–835. 2010. .
   Google Scholar
• Chamseddine AN, Ducreux M, Armand JP, et al. Intestinal bacterial β-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity. Pharmacol Ther. 2019;199:1–15.
   Google Scholar
• Nakao T, Kurita N, Komatsu M, et al. Irinotecan injures tight junction and causes bacterial translocation in rat. J Surg Res. 2012;173(2):341–347.
   Google Scholar
• Gandhi A, Moorthy B, Ghose R. Drug disposition in pathophysiological conditions. Curr Drug Metab. 2012 Oct 11;13(9):1327–1344.
   Google Scholar
• Zollner G, Wagner M, Trauner M. Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. Pharmacol Ther. 2010;228–243. DOI:10.1016/j.pharmthera.2010.03.005
   Google Scholar
• Gregory PA, Lewinsky RH, Gardner-Stephen DA, et al. Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol Appl Pharmacol. 2004;199(3):354–363.
   Google Scholar
• Mubarokah N, Hulin JA, Mackenzie PI, et al. Cooperative regulation of intestinal udp-glucuronosyltransferases 1A8, −1A9, and 1A10 by CDX2 and HNF4a is mediated by a novel composite regulatory elements. Mol Pharmacol. 2018;93(5):541–552.
   Google Scholar
• Ihunnah CA, Jiang M, Xie W. Nuclear receptor PXR, transcriptional circuits and metabolic relevance. Biochim Biophys Acta - Mol Basis Dis. 2011;1812(8):956–963.
   Google Scholar
• Satarug S, Lang MA, Yongvanit P, et al. Induction of cytochrome P450 2A6 expression in humans by the carcinogenic parasite infection, opisthorchiasis viverrini. Cancer Epidemiol Prev Biomarkers. 1996;5(10):795–800.
   Google Scholar
• Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol. 2006;46(1):123–149.
   Google Scholar
• Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42(2):145–151.
   Google Scholar
• Ghose R, Guo T, Vallejo JG, et al. Differential role of toll-interleukin 1 receptor domain-containing adaptor protein in toll-like receptor 2-mediated regulation of gene expression of hepatic cytokines and drug-metabolizing enzymes. Drug Metab Dispos. 2011;39(5):874–881.
   Google Scholar
• Shah P, Omoluabi O, Moorthy B, et al. Role of adaptor protein toll-like interleukin domain containing adaptor inducing interferon b in toll-like receptor 3- and 4-mediated regulation of hepatic drug metabolizing enzyme and transporter genes. Drug Metab Dispos. 2016;44(1):61–67.
   Google Scholar
• Kagan JC, Su T, Horng T, et al. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-β. Nat Immunol. 2008;9(4):361–368.
   Google Scholar
• Shah P, Guo T, Moore DD, et al. Role of constitutive androstane receptor in toll-like receptor-mediated regulation of gene expression of hepatic drug-metabolizing enzymes and transporters. Drug Metab Dispos. 2014;42(1):172–181.
   Google Scholar
• Mallick P, Basu S, Moorthy B, et al. Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro. Toxicol Vitr. 2017;41:75–82.
   Google Scholar
• Chen JQ, Strom A, Gustafsson JA, et al. Suppression of the constitutive expression of cytochrome P-450 2C11 by cytokines and interferons in primary cultures of rat hepatocytes: comparison with induction of acute-phase genes and demonstration that CYP2C11 promoter sequences are involved in the s. Mol Pharmacol. 1995;47(5):940–947.
   Google Scholar
• Siewert E, Bort R, Kluge R, et al. Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology. 2000;32(1):49–55.
   Google Scholar
• Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 2007;35(9):1687–1693.
   Google Scholar
• Ashino T, Oguro T, Shioda S, et al. Involvement of interleukin-6 and tumor necrosis factor α in CYP3A11 and 2C29 down-regulation by bacillus Calmette-Guerin and, lipopolysaccharide in mouse liver. Drug Metab Dispos. 2004;32(7):707–714.
   Google Scholar
• Hu N, Huang Y, Gao X, et al. Effects of dextran sulfate sodium induced experimental colitis on cytochrome P450 activities in rat liver, kidney and intestine. Chem Biol Interact [Internet]. 2017;271:48–58.
   Google Scholar
• Erdmann P, Bruckmueller H, Martin P, et al. Dysregulation of mucosal membrane transporters and drug-metabolizing enzymes in ulcerative colitis. J Pharm Sci. 2019;108(2):1035–1046.
   Google Scholar
• Mallick P, Shah P, Gandhi A, et al. Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice. Life Sci. 2015;132–138. DOI:10.1016/j.lfs.2015.08.017
   Google Scholar
• Nusse R, Clevers H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985–999.
   Google Scholar
• Braeuning A, Köhle C, Buchmann A, et al. Coordinate regulation of cytochrome P450 1a1 expression in mouse liver by the aryl hydrocarbon receptor and the β-catenin pathway. Toxicol Sci. 2011;122(1):16–25.
   Google Scholar
• Thompson MD, Monga SPS. WNT/β-catenin signaling in liver health and disease. Hepatology. 2007;45(5):1298–1305.
   Google Scholar
• Braeuning A. Regulation of cytochrome P450 expression by Ras- and β-catenin-dependent signaling. Curr Drug Metab. 2009;10(2):138–158.
   Google Scholar
• Loeppen S, Koehle C, Buchmann A, et al. A β-catenin-dependent pathway regulates expression of cytochrome P450 isoforms in mouse liver tumors. Carcinogenesis. 2005;26(1):239–248.
   Google Scholar
• Briolotti P, Chaloin L, Balaguer P, et al. Analysis of glycogen synthase kinase inhibitors that regulate cytochrome P450 expression in primary human hepatocytes by activation of β-catenin, aryl hydrocarbon receptor and pregnane X receptor signaling. Toxicol Sci. 2015;148(1):261–275.
   Google Scholar
• Sekine S, Lan BYA, Bedolli M, et al. Liver-specific loss of β-catenin blocks glutamine synthesis pathway activity and cytochrome P450 expression in mice. Hepatology. 2006;43(4):817–825.
   Google Scholar
• Tsang LLH, Quarterman CP, Gescher A, et al. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother Pharmacol. 1991;27(5):342–346.
   Google Scholar
• Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol. 1987;5(10):1559–1565.
   Google Scholar
• Lamba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009;10(10):1657–1674.
   Google Scholar
• Zhuo X, Zheng N, Felix CA, et al. Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004;32(9):993–1000.
   Google Scholar
• Jacobson P, Green K, Birnbaum A, et al. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol. 2002;49(6):461–467.
   Google Scholar
• Aparicio-Gallego G, Blanco M, Figueroa A, et al. New insights into molecular mechanisms of sunitinib-associated side effects. Mol Cancer Ther. 2011;10(12):2215–2223.
   Google Scholar
• Cyclophosphamide [Internet]. LiverTox: clinical and research information on drug-induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012. [accessed 2020 Aug 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31643390
   Google Scholar
• McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003;101(5):2043–2048.
   Google Scholar
• Jain M, Fan J, Baturay NZ, et al. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines. J Med Chem. 2004;47(15):3843–3852.
   Google Scholar
• Petrillo SK, Desmeules P, Truong TQ, et al. Detection of DNA damage in oocytes of small ovarian follicles following phosphoramide mustard exposures of cultured rodent ovaries in vitro. Toxicol Appl Pharmacol. 2011;253(2):94–102.
   Google Scholar
• McQuade RM, Stojanovska V, Abalo R, et al. Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments. Front Pharmacol. 2016;7:1–14.
   Google Scholar
• Fluorouracil [Internet]. LiverTox: clinical and research information on drug-induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012. [accessed 2020 Aug 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31644088
   Google Scholar
• Wei X, McLeod HL, McMurrough J, et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest. 1996;98(3):610–615.
   Google Scholar
• Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU toxicity study group. J Clin Oncol. 2008;26(13):2131–2138.
   Google Scholar
• Pullarkat ST, Lenz HJ. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 2001;1(1):65–70.
   Google Scholar
• Afzal S, Gusella M, Vainer B, et al. Combinations of polymorphisms in genes involved in the 5-fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients. Clin Cancer Res. 2011;17(11):3822–3829.
   Google Scholar
• Prado CMM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13(11):3264–3268.
   Google Scholar
• Daniele B, Perrone F, Gallo C, et al. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: A double blind, placebo controlled, randomised trial. Gut. 2001;48(1):28–33.
   Google Scholar
• Saif MW, Diasio RB. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency. Cancer Chemother Pharmacol. 2016;78(1):151–156.
   Google Scholar
• Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol. 2002;13(12):1841–1851.
   Google Scholar
• Irinotecan [Internet]. LiverTox: clinical and research information on drug-induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012. [accessed 2020 Aug 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31643368
   Google Scholar
• de Man FM, Goey AKL, van Schaik RHN, et al. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 2018;57(10):1229–1254.
   Google Scholar
• Campbell JM, Stephenson MD, Bateman E. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenomics J. 2017;17(1):21–28.
   Google Scholar
• Innocenti F, Undevia SD, Ramírez J, et al. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther. 2004;76(5):490–502.
   Google Scholar
• Michael M, Brittain MA, Nagai J, et al. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol. 2004;22(21):4410–4417.
   Google Scholar
• Lam W, Bussom S, Guan F, et al. Chemotherapy: the four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med. 2(45): 1–10. 2010. .
   Google Scholar
• Tao G, Dagher F, Moballegh A, et al. Role of oxidative stress in the efficacy and toxicity of herbal supplements. Curr Opin Toxicol. 2020;20:36–40.
   Google Scholar
• Liu X, Situ A, Kang Y, et al. Irinotecan delivery by lipid-coated mesoporous silica nanoparticles shows improved efficacy and safety over liposomes for pancreatic cancer. ACS Nano. 2016;10(2):2702–2715.
   Google Scholar
• Paludetto MN, Puisset F, Chatelut E, et al. Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: implications for drug-drug interactions and hepatotoxicity. Med Res Rev. 2019;39(6):2105–2152.
   Google Scholar
• Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633–640.
   Google Scholar
• Aithal GP. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Int. 2015;35(7):1801–1808.
   Google Scholar
• Castellino S, O’Mara M, Koch K, et al. Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity. Drug Metab Dispos. 2012;40(1):139–150.
   Google Scholar
• Hardy KD, Wahlin MD, Papageorgiou I, et al. Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells. Drug Metab Dispos. 2014;42(1):162–171.
   Google Scholar
• Li X, Kamenecka TM, Cameron MD. Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities. Chem Res Toxicol. 2009;22(10):1736–1742.
   Google Scholar
• Liu X, Lu Y, Guan X, et al. Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism. Biochem Pharmacol. 2015;97(1):111–121.
   Google Scholar
• Ma Y, Xin S, Huang M, et al. Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): A pharmacogenomic study of metabolic enzymes and transporters. Pharmacogenomics J. 2017;17(4):325–330.
   Google Scholar
• Bonvin A, Mesnil A, Nicolini FE, et al. Dasatinib-induced acute hepatitis. Leuk Lymphoma. 2008;49(8):1630–1632.
   Google Scholar
• Li X, He Y, Ruiz CH, et al. Correction to “Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways” (Drug Metabolism and Disposition (2009) 37, (1242–1250)). Drug Metab Dispos. 2009;37(10):2118.
   Google Scholar
• Li X, Kamenecka TM, Cameron MD. Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile. Drug Metab Dispos. 2010;38(7):1238–1245.
   Google Scholar
• Paludetto MN, Bijani C, Puisset F, et al. Metalloporphyrin-catalyzed oxidation of sunitinib and pazopanib, two anticancer tyrosine kinase inhibitors: evidence for new potentially toxic metabolites. J Med Chem. 2018;61(17):7849–7860.
   Google Scholar
• Teng WC, Oh JW, New LS, et al. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010;78(4):693–703.
   Google Scholar
• Barbara JE, Kazmi F, Parkinson A, et al. Metabolism-dependent inhibition of CYP3A4 by lapatinib: evidence for formation of a metabolic intermediate complex with a nitroso/oxime metabolite formed via a nitrone intermediate. Drug Metab Dispos. 2013;41(5):1012–1022.
   Google Scholar
• Filppula AM, Neuvonen PJ, Backman JT. In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014;42(7):1202–1209.
   Google Scholar
• Harmsen S, Meijerman I, Beijnen JH, et al. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: A key role for the pregnane X receptor. Cancer Chemother Pharmacol. 2009;64(1):35–43.
   Google Scholar
• Esposito G, Nobile N, Gigli S, et al. Rifaximin improves clostridium difficile toxin A-induced toxicity in Caco-2 cells by the PXR-dependent TLR4/MyD88/NF-κB pathway. Front Pharmacol. 2016;7:120.
   Google Scholar
• Chen J, Peng Y, Zheng J. Cytochrome P450 mediated bioactivation of saracatinib. Chem Res Toxicol. 2016;29(11):1835–1842.
   Google Scholar
• Rae JM, Soukhova NV, Flockhart DA. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos. 2002;30(5):525–530.
   Google Scholar
• Kenny JR, Mukadam S, Zhang C, et al. Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction. Pharm Res. 2012;29(7):1960–1976.
   Google Scholar
• Jones HM, Barton HA, Lai Y, et al. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos. 2012;40(5):1007–1017.
   Google Scholar
• Kumar V, Salphati L, Hop CECA, et al. A comparison of total and plasma membrane abundance of transporters in suspended, plated, sandwich-cultured human hepatocytes versus human liver tissue using quantitative targeted proteomics and cell surface biotinylation S. Drug Metab Dispos. 2019;47(4):350–357.
   Google Scholar
• Badolo L, Jensen B, Säll C, et al. Evaluation of 309 molecules as inducers of CYP3A4, CYP2B6, CYP1A2, OATP1B1, OCT1, MDR1, MRP2, MRP3 and BCRP in cryopreserved human hepatocytes in sandwich culture. Xenobiotica. 2015;45(2):177–187.
   Google Scholar
• Knowlton S, Tasoglu S. A bioprinted liver-on-a-chip for drug screening applications. Trends Biotechnol. 2016;34:681–682.
   Google Scholar
• Kim HJ, Li H, Collins JJ, et al. Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. Proc Natl Acad Sci U S A. 2016;113(1):E7–15.
   Google Scholar
• Van Waterschoot RAB, Rooswinkel RW, Sparidans RW, et al. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam. Drug Metab Dispos. 2009;37(12):2305–2313.
   Google Scholar
• Cai H, Nguyen N, Peterkin V, et al. A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation. Drug Metab Dispos. 2010;38(5):879–886.
   Google Scholar
• Hasegawa M, Kapelyukh Y, Tahara H, et al. Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line. Mol Pharmacol. 2011;80(3):518–528.
   Google Scholar
• Galteau MM, Shamsa F .Urinary 6β-hydroxycortisol: A validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol. 2003:713–733. Springer. DOI: 10.1007/s00228-003-0690-3.
   Google Scholar
• Abdulla D, Goralski KB, Garcia Del Busto Cano E, et al. The signal transduction pathways involved in hepatic cytochrome p450 regulation in the rat during a lipopolysaccharide-induced model of central nervous system inflammation. Drug Metab Dispos. 2005;33(10):1521–1531.
   Google Scholar
• Mallick P, Shah P, Ittmann MM, et al. Impact of diet on irinotecan toxicity in mice. Chem Biol Interact. 2018;291:87–94.
   Google Scholar